Efficacy of Intravenous Nefopam, Dexmedetomidine, and Meperidine in Preventing Post-Spinal Anesthesia Shivering in Adult Patients Undergoing Lower Abdominal and Lower Limb Surgeries: A Double-Blind Comparative Study

This prospective, randomized, controlled, double-blinded study is designed to evaluate the efficacy of nefopam compared to dexmedetomidine and meperidine for the prevention of postspinal anesthesia shivering while minimizing side effects.

Start Date01 Oct 2024

Sponsor / Collaborator

Qasr El Eyni Hospital

ChiCTR2400085625 / SuspendedEarly Phase 1IIT

Effect of Nefopam in the treatment of catheter-related bladder discomfort after gynecological surgery

Start Date17 Jun 2024

Sponsor / Collaborator-

TCTR20240412003 / Not yet recruitingPhase 4IIT

Analgesic efficacy of Nefopam after Arthroscopic Anterior cruciate ligament reconstruction surgery: A Prospective, Tripple-blind, randomized controlled trial

Start Date02 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Nefopam Hydrochloride

100 Translational Medicine associated with Nefopam Hydrochloride

100 Patents (Medical) associated with Nefopam Hydrochloride

455

Literatures (Medical) associated with Nefopam Hydrochloride

01 Dec 2024·Anaesthesia Critical Care & Pain Medicine

Opioid free versus opioid sparing strategies for multimodal antinociception during laparoscopic colectomy: a randomised controlled trial

Article

Author: Ramadan, Joanna ; Collange, Vincent ; Parent, Sebastien ; Aubrun, Frederic ; Noel, Philippe ; Berruet, Jean Baptiste ; Poiblanc, Marie ; Olagne, Eric ; Perrou, Maya ; Mercier, Nadège Golliet ; Joosten, Alexandre ; Devillez, Simon ; Golliet Mercier, Nadège ; Coeckelenbergh, Sean

BACKGROUNDIt remains unclear whether opioid-free anesthesia (OFA), when compared to opioid-sparing anesthesia (OSA), reduces postoperative opioid consumption while still providing adequate pain control. We thus tested the hypothesis that patients having an OFA strategy during laparoscopic colectomy would require less postoperative opioids when compared to an OSA strategy.METHODSThis single-center, prospective randomized controlled superiority trial, randomly allocated consecutive patients undergoing laparoscopic colectomy to receive either sevoflurane-dexmedetomidine anesthesia with a continuous infusion of lidocaine and ketamine (OFA group) or sevoflurane-sufentanil boluses anesthesia with a continuous infusion of lidocaine (OSA group). Both groups received multimodal antinociception with boluses of dexamethasone, lidocaine, and ketamine during anesthesia induction, as well as acetaminophen, ketoprofen, and nefopam before the end of the surgery. OFA patients also received a dose of magnesium sulfate during induction. The primary outcome was cumulative opioid consumption at 48 h after surgery, expressed in oral morphine equivalents (OME). Secondary exploratory outcomes were pain scores, opioid-related adverse events, and patient quality of life (WHODAS score).RESULTSOf the 160 randomized patients, 155 were included in a modified intention-to-treat analysis. Median [Q1-Q3] OME consumption at 48 h after surgery did not differ between groups (9 [0-30] mg for OFA vs. 14 [0-30] mg for OSA; p = 0.861). Key secondary outcomes were not different between groups except a three time higher incidence of bradycardia in the OFA group.CONCLUSIONSIn patients undergoing laparoscopic colectomy with a multimodal antinociception protocol, OFA, when compared to OSA, did not decrease postoperative opioid consumption.CLINICAL TRIAL REGISTRY AND NUMBERNCT05031234.

01 Nov 2024·Public Health

Trends in fatal poisoning among medical users of analgesics in France from 2013 to 2022: an analysis of the DTA register

Article

Author: Loilier, Magalie ; Delage, Martine ; Spadari, Michel ; Pineau, Alain ; Titier, Karine ; Billet-Chatenay, Camille ; Lamiable, Denis ; Hoizey, Guillaume ; Dumestre-Toulet, V. ; Allorge, Delphine ; Bertin, Célian ; Scala-Bertola, Julien ; Abbara, Chadi ; Martin-Molins, Claire ; Revol, B. ; Lacroix, Christian ; Lavit, Michel ; Le Boisselier, Reynald ; Klinzig, Florian ; Visinoni, Pascale ; Kintz, Pascal ; Pépin, Gilbert ; Mathieu, Olivier ; Saussereau, Elodie ; Sabini, Sandrine ; Pok, Rop ; Mura, Patrick ; Pelissier-Alicot, Anne-Laure ; Lelong-Boulouard, Véronique ; Morel, Isabelle ; Manceau, M. ; Bouquet, Emilie ; Berland, Emilie ; Descoeur, Juliette ; Bevalot, Fabien ; Descamps, Florence ; Caous, Anne-Sylvie ; Dailly, Eric ; Doche, Christophe ; Venisse, Nicolas ; Le Meur, Catherine ; Mathieu-Daudé, Jean-Claude ; Delavenne, Xavier ; Lacarelle, Bruno ; Eysseric-Guérin, H. ; Labat-Deveaux, Laurence ; Alvarez, Jean-Claude ; Ameline, Alice ; Gérardin, Marie ; Gaillard, Yvan ; Gaulier, J.-M. ; Lopez, Vincent ; Collon-Fabie, Philippe ; Cesbron, Alexandre ; Turcant, Alain ; Rayer, Raphaël ; Deffontaine, Grégory ; Citterio-Quentin, Antony ; Fouley, Aurélie ; Cheze, Marjorie ; Ragoucy-Sengler, Catherine ; Moal, Aurélie ; Redjimi, Nassima ; Gambier, Nicolas ; Barret, Anne ; Goullé, Jean-Pierre ; Sibille, Pauline ; Bourgine, Joanna ; Pochard, Liselotte ; Peyre, Anne ; Deveaux, Marc ; Lemaire-Hurtel, Anne-Sophie ; Humbert, Luc ; Guerard, Pascal ; Fouilhé Sam-Laï, N. ; Thiery, Johan ; Lefeuvre, Sandrine ; Charuel, Lauriane ; Perrin, Martine ; Roman, Emilie ; Milan, Nathalie ; Boucher, Alexandra ; Le Bouil, Anne ; Kergueris, Marie-France ; Lelièvre, Bénédicte ; Eiden, Céline ; Ganière, Catherine ; Daveluy, Amélie ; Brunet, Bertrand ; Mauras, Yves ; Devos, Bernadette ; Vacher, Pierrick ; Willeman, T. ; Deslandes, Guillaume ; Vieira, Ophélie ; Imbert, Laurent ; Roussel, Carine ; Besnard, Thierry ; Marty, Hélène

OBJECTIVETo describe analgesic-related deaths in France and report trends over a 10-year period.STUDY DESIGNThe DTA ("Décès Toxiques par Antalgiques") register is a French database of analgesic-related deaths among people without a history of drug abuse, reported by forensic toxicology experts.METHODSWe included analgesic-related deaths occurring from January 2013 to December 2022 in France. Subject demographic characteristics and medical history, forensic autopsy findings, and toxicology reports were evaluated.RESULTSAmong the 1036 deceased individuals (mean [SD] age, 48.3 [15.6] years), there were slightly more women than men (M:F sex ratio, 0.89:1). Over the entire study period, tramadol was the leading cause of death, ahead of morphine. A relative increase in oxycodone-related mortality was observed (from 6.8% in 2013 to 21.1% in 2022) compared to a progressive decrease in tramadol, morphine, and codeine-related deaths (from 43.2%, 31.1% and 24.3% in 2013 to 37.5%, 26.6% and 20.3% in 2022, respectively). However, no statistically significant variations were found (Chi-squared tests of homogeneity). Other analgesics (buprenorphine, dihydrocodeine, fentanyl, gabapentin, ketamine, methadone, nefopam, and pregabalin) were also implicated in deaths, but with low and stable rates over the period studied.CONCLUSIONSIn France, no increase in fentanyl-related deaths and only a non-significant increase in oxycodone-related deaths were observed over the period 2013-2022. Tramadol was the leading cause of analgesic-related deaths throughout this period. Although close monitoring is still required, particularly for oxycodone, our data do not support the hypothesis of an opioid crisis in France.

01 Nov 2024·European Journal of Anaesthesiology

Pain management after laparoscopic cholecystectomy

Review

Author: Van de Velde, Marc ; Sauter, Axel R ; Joshi, Girish P ; Oyaert, Lukasa ; Bourgeois, Camille ; Pogatzki-Zahn, Esther ; Freys, Stephan M ; Dewinter, Geertrui ; Oyaert, Lukas

Laparoscopic cholecystectomy can be associated with significant postoperative pain that is difficult to treat. We aimed to evaluate the available literature and develop updated recommendations for optimal pain management after laparoscopic cholecystectomy. A systematic review was performed using the procedure-specific postoperative pain management (PROSPECT) methodology. Randomised controlled trials and systematic reviews published in the English language from August 2017 to December 2022 assessing postoperative pain after laparoscopic cholecystectomy using analgesic, anaesthetic or surgical interventions were identified from MEDLINE, Embase and Cochrane Databases. From 589 full text articles, 157 randomised controlled trials and 31 systematic reviews met the inclusion criteria. Paracetamol combined with NSAIDs or cyclo-oxygenase-2 inhibitors should be given either pre-operatively or intra-operatively, unless contraindicated. In addition, intra-operative intravenous (i.v.) dexamethasone, port-site wound infiltration or intraperitoneal local anaesthetic instillation are recommended, with opioids used for rescue analgesia. As a second-line regional technique, the erector spinae plane block or transversus abdominis plane block may be reserved for patients with a heightened risk of postoperative pain. Three-port laparoscopy, a low-pressure pneumoperitoneum, umbilical port extraction, active aspiration of the pneumoperitoneum and saline irrigation are recommended technical aspects of the operative procedure. The following interventions are not recommended due to limited or no evidence on improved pain scores: single port or mini-port techniques, routine drainage, low flow insufflation, natural orifice transluminal endoscopic surgery (NOTES), infra-umbilical incision, i.v. clonidine, nefopam and regional techniques such as quadratus lumborum block or rectus sheath block. Several interventions provided better pain scores but are not recommended due to risk of side effects: spinal or epidural anaesthesia, gabapentinoids, i.v. lidocaine, i.v. ketamine and i.v. dexmedetomidine.

100 Deals associated with Nefopam Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D05133	Nefopam Hydrochloride	N02BG06	DB12293

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1985

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TCTR20181016001 (Pubmed)	Not Applicable	Cancer Pain	40	Nefopam	jjemwfgfau(cresvzlfas) = ofwaytyqjs ypuggqepis (ljbcjwcmiq )	-	01 Jan 2020
				Placebo	jjemwfgfau(cresvzlfas) = rknlvnohgo ypuggqepis (ljbcjwcmiq )
NCT01461031 (Pubmed \| J Craniomaxillofac Surg) Manual	Not Applicable	Pain, Postoperative	42	nefopam	(kfeffbvmem) = peforzofwp exczkeybvy (nuyyapyuwn )	Positive	01 Feb 2016
				Placebo	(kfeffbvmem) = nwnkcnqgth exczkeybvy (nuyyapyuwn )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis